STRO vs WY · rev $62.0M vs P/E 43, rev $7.12B
Sutro Biopharma (STRO) versus Weyerhaeuser Company (WY) — a side-by-side from cached financials, not a winner call.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Weyerhaeuser Company (WY) is a reit - specialty company listed on NYSE.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
Latest reported WY revenue for 2024-12-31 was $7.12B. Net income was $396.0M. Revenue was down 7.2% from 2023-12-31 to 2024-12-31. WY currently screens at market cap $17.54B and trailing P/E 43.4.
STRO currently screens at market cap $470.8M. WY currently screens at market cap $17.54B and trailing P/E 43.4.
Not investment advice. Open the STRO and WY stock pages for the full models.
Not investment advice.